Costs of blood transfusion: a process-flow analysis

• Published in: Journal of clinical oncology Vol. 16; no. 7; p. 2364
• Main Authors: Cantor, S B, Hudson, Jr, D V, Lichtiger, B, Rubenstein, E B
• Format: Journal Article
• Language: English
• Published: United States 01.07.1998
• Subjects: Accounting; Ambulatory Care; Blood Banks - economics; Bone Marrow Transplantation - economics; Cancer Care Facilities - economics; Cost Allocation; Erythrocyte Transfusion - economics; Hospital Costs - statistics & numerical data; Humans; Neoplasms - economics; Neoplasms - therapy; Process Assessment (Health Care) - economics; Task Performance and Analysis; Texas; Texas
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.1998.16.7.2364

To determine the cost of transfusing 2 units (U) of packed RBCs at a comprehensive cancer center. We performed a process-flow analysis to identify all costs of transfusing 2 U of allogeneic packed RBCs on an outpatient basis to patients with either (1) solid tumor who did not undergo bone marrow transplantation (BMT), (2) solid tumor who underwent BMT, (3) hematologic malignancy who did not undergo BMT, (4) hematologic malignancy who underwent allogeneic BMT, or (5) hematologic malignancy who underwent autologous BMT. We conducted structured interviews to determine the personnel time used and physical resources necessary at all steps of the transfusion process. The mean cost of a 2-U transfusion of allogeneic packed RBCs was $548, $565, $569, $569, and $566 for patients with non-BMT solid tumor, BMT solid tumor, non-BMT hematologic malignancy, allogeneic BMT hematologic malignancy, and autologous BMT hematologic malignancy, respectively. Sensitivity analysis showed that total transfusion costs were sensitive to variations in the amount of clinician compensation and overhead costs, but were relatively insensitive to reasonable variations in the direct costs of blood tests and the blood itself, or the probability or extent of transfusion reaction. The costs of the transfusion of packed RBCs are greater than previously analyzed, particularly in the cancer care setting.